Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 3:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 803 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Inherited Ophthalmic Diseases Clear all
Completed Phase 2 Interventional Results available

Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease

NCT02023866
View directory record Official record
Conditions
Inherited Mitochondrial Disease, Including Leigh Syndrome
Interventions
Cysteamine Bitartrate
Drug
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
San Diego, California • Stanford, California • Akron, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 5, 2026, 3:32 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Rod and Cone Mediated Function in Retinal Disease

NCT02617966
View directory record Official record
Conditions
Retinal Degeneration, Retinitis Pigmentosa, Stargardt's Disease
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
5 Years to 100 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 5, 2026, 3:32 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Comparative Autoantibody and Immunologic Cell Marker Study

NCT02422875
View directory record Official record
Conditions
Autoimmune Diseases, Lupus Erythematosus, Systemic, Communicable Diseases
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2028
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 5, 2026, 3:32 PM EDT
Completed Phase 3 Interventional

A Treatment Protocol for the Use of Intravenous Ganciclovir in AIDS Patients With Immediately Sight-Threatening CMV Retinitis

NCT00000698
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 30, 2008 · Synced Oct 5, 2026, 3:32 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Gait Analysis in Neurological Disease

NCT02994719
View directory record Official record
Conditions
Parkinson's Disease, Parkinsonian Disorders, Atypical Parkinson Disease, Progressive Supranuclear Palsy, Multiple System Atrophy, Corticobasal Degeneration, Gait, Frontal, Huntington Disease, Ataxia, Spinocerebellar
Interventions
Anti-Parkinson medication, Deep Brain Stimulation
Drug · Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 5, 2026, 3:32 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus)

NCT06792500
View directory record Official record
Conditions
MELAS Syndrome, Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus)
Interventions
Glycerol Tributyrate
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 5, 2026, 3:32 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A

NCT00000116
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
Vitamin A, Docosahexaenoic acid, Control fatty acid
Dietary Supplement
Lead sponsor
Carol Weigel DiFranco
NIH
Eligibility
18 Years to 55 Years
Enrollment
221 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2002
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2023 · Synced Oct 5, 2026, 3:32 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD

NCT04704921
View directory record Official record
Conditions
AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, Wet AMD, CNV, Neovascular AMD, Neovascular Age-related Macular Degeneration, Choroidal Neovascularization
Interventions
ABBV-RGX-314, Ranibizumab (LUCENTIS®)
Genetic · Biological
Lead sponsor
AbbVie
Industry
Eligibility
50 Years to 89 Years
Enrollment
671 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
89
States / cities
Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 77 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 5, 2026, 3:32 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Vestibular Precision: Physiology & Pathophysiology

NCT04890132
View directory record Official record
Conditions
Vestibular Schwannoma, Inner Ear Disease, Dizziness, Neurofibromatosis 2, Vestibular Disorder
Interventions
VOR precision training
Behavioral
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
8 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Oct 5, 2026, 3:32 PM EDT
Completed Phase 2 Interventional

Carboplatin Plus Vincristine in Treating Children With Retinoblastoma

NCT00002794
View directory record Official record
Conditions
Retinoblastoma
Interventions
carboplatin, vincristine sulfate
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 10 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2001
U.S. locations
2
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 4, 2011 · Synced Oct 5, 2026, 3:32 PM EDT
Completed No phase listed Observational

Reproductive Health in Men and Women With Vasculitis

NCT02176070
View directory record Official record
Conditions
Giant Cell Arteritis, Takayasu's Arteritis, Polyarteritis Nodosa, Wegener's Granulomatosis, Microscopic Polyangiitis, Churg-Strauss Syndrome, Behcet's Disease, Kawasaki Disease, Henoch-schoenlein Purpura, Vasculitis, Central Nervous System, Drug-induced Necrotizing Vasculitis
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Oct 5, 2026, 3:32 PM EDT
Completed Not applicable Interventional

Restorative Eye Treatment and INhance in Upper Eyelid Blepharoplasty Surgery

NCT05007288
View directory record Official record
Conditions
Eyelid Dermatochalasis, Dermatochalasis
Interventions
Restorative Eye Treatment (RET) cream, INhance with Trihex Technology
Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Oct 5, 2026, 3:32 PM EDT
Completed Phase 3 Interventional

Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV Retinitis

NCT00002070
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Sargramostim, Ganciclovir
Drug
Lead sponsor
Schering-Plough
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • Sherman Oaks, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 5, 2026, 3:32 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

National Eye Institute Biorepository for Retinal Diseases

NCT01496625
View directory record Official record
Conditions
Age-Related Macular Degeneration, Diabetic Retinopathy, Von Hippel-Lindau Syndrome, Retinal Disease, Retinal Vein Occlusion
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
2 Years to 120 Years
Enrollment
650 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 5, 2026, 3:32 PM EDT
Completed Phase 3 Interventional Results available

Efficacy & Safety Study of Bilateral IVT Injection of GS010 in LHON Subjects Due to the ND4 Mutation for up to 1 Year

NCT03293524
View directory record Official record
Conditions
Leber Hereditary Optic Neuropathy
Interventions
GS010, Placebo
Genetic · Drug
Lead sponsor
GenSight Biologics
Industry
Eligibility
15 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
7
States / cities
Pasadena, California • Aurora, Colorado • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 5, 2026, 3:32 PM EDT
Completed Phase 4 Interventional Results available

Saline vs. Lactated Ringers for Emergency Department IV Fluid Resuscitation

NCT03133767
View directory record Official record
Conditions
Fluid Loss, Symptom Complex, Triple, Emergencies
Interventions
Lactated Ringer Solution, Normal Saline 0.9% Infusion Solution Bag
Drug
Lead sponsor
Nicholas M Mohr
Other
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 5, 2026, 3:32 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D

NCT03920007
View directory record Official record
Conditions
Leber Congenital Amaurosis, LCA, LCA1
Interventions
ATSN-101, ATSN-101 Diluent Solution, Prednisone, Triamcinalone Acetonide, 1% Prednisolone, Trimethoprim/polymyxin B
Drug
Lead sponsor
Atsena Therapeutics Inc.
Industry
Eligibility
6 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Portland, Oregon • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 5, 2026, 3:32 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The Evaluation of Balanced Salt Solution During Cataract Surgery

NCT05853978
View directory record Official record
Conditions
Fuchs Dystrophy, Cataract
Interventions
BSS Plus, BSS
Drug
Lead sponsor
Adam Fedyk, MD, FACS
Other
Eligibility
22 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Town and Country, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 5, 2026, 3:32 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Validation of i-ROP DL to Detect More Than Mild ROP

NCT06109285
View directory record Official record
Conditions
Retinopathy of Prematurity, ROP
Interventions
iROP DL
Device
Lead sponsor
Siloam Vision
Industry
Eligibility
20 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 5, 2026, 3:32 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of SAR421869 in Participants With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B

NCT01505062
View directory record Official record
Conditions
Usher Syndrome, Retinitis Pigmentosa
Interventions
SAR421869
Drug
Lead sponsor
Sanofi
Industry
Eligibility
6 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Oct 5, 2026, 3:32 PM EDT
Enrolling by invitation Phase 2 Interventional

ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study

NCT05481827
View directory record Official record
Conditions
Age Related Macular Degeneration (AMD)
Interventions
GT005
Genetic
Lead sponsor
Gyroscope Therapeutics Limited
Industry
Eligibility
55 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
22
States / cities
Poway, California • Durango, Colorado • Gainesville, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 5, 2026, 3:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Comparison of the Effect of Suture Material on Blepharoplasty Incision

NCT04585217
View directory record Official record
Conditions
Dermatochalasis, Ptosis, Eyelid
Interventions
Randomized laterality of suture materials for closure (6-0 polypropylene monofilament suture vs fast absorbing gut suture on right eyelid)
Procedure
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years to 89 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 5, 2026, 3:32 PM EDT
Completed Not applicable Interventional

An Open Label Evaluation of the Safety and Pharmacokinetics of Ganciclovir in Children

NCT00002015
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Ganciclovir
Drug
Lead sponsor
Roche Global Development
Other
Eligibility
3 Months to 12 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 5, 2026, 3:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Environmental Localization Mapping and Guidance for Visual Prosthesis Users

NCT04359108
View directory record Official record
Conditions
Retinitis Pigmentosa, Visual Impairment, Visual Prosthesis
Interventions
Navigation system mode: Argus Vision, Navigation system mode: Depth Vision, Navigation system mode: Depth Vision with Haptic / Audio, Navigation system mode: Haptic / Audio, Navigation system mode: High Field-of-View Depth Vision, Distance test vision mode: Low Resolution / Low Field-of-View, Distance test vision mode: Low Resolution / High Field-of-View, Distance test vision mode: High Resolution / Low Field-of-View, Distance test vision mode: High Resolution / High Field-of-View
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
2
States / cities
Baltimore, Maryland • Laurel, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 5, 2026, 3:32 PM EDT